This week's roundup of Houston innovators includes Armand Paradis of ComboCurve, Matthew Nojoomi of Ictero Medical, and Ryan McCord of McCord Development. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to energy software — recently making headlines in Houston innovation.

Armand Paradis, co-founder of ComboCurve

Armand Paradis joins the Houston Innovators Podcast to discuss how his energy software business is scaling rapidly. Photo courtesy

Houston-based ComboCurve is growing rapidly. The energy software company has raised over $60 million in venture capital investment — $50 million of which was closed in the company’s series B round earlier this year. Since the original product launched in May of 2020, CEO and Co-Founder Armand Paradis says the platform has almost 200 companies on it.

“We built something that resonated with the market — and we were super passionate about the product and taking care of our industry,” Paradis says on the Houston Innovators Podcast. “We don’t want to be the best in oil and gas. We want to be the best software company."Click here to read more.

Matthew Nojoomi, CEO and co-founder of Ictero Medical

This innovative medical device company has closed $6 million for further product development and clinical trials. Image via TMC.edu

Houston-based medical device company Ictero Medical closed its oversubscribed series A at $6 million. The funding round was led by MedTex Ventures, S3 Ventures, and an undisclosed strategic investor. The company's novel cryoablation system was designed to treat high-risk gallstone disease patients and provide a less invasive and lower risk alternative to gallbladder removal surgery — something over 1 million Americans undergo annually.

“Our technology provides an immediate solution for critically ill patients who currently have no good treatment options, and also has the potential to benefit healthier patients who want to avoid surgery,” says Ictero Co-Founder and CEO Matthew Nojoomi in the release. Click here to read more.

Ryan McCord, president of McCord Development

Houston real estate expert shares why he thinks the city is prime for smart city tech and implementation. Photo courtesy

Houston has every tool in its toolkit to be able to emerge as a smart city leader. In a guest column for InnovationMap, Ryan McCord of McCord Development explains the momentum the city already has and the existing smart city opportunities already in town.

"Houston’s diversity, business-friendly environment, and workforce make it a prime candidate to become a smart city. Becoming smarter in our transportation, public safety, sustainability practices, and infrastructure will create a better future for Houstonians." Click here to read more.

This innovative medical device company has closed $6 million for further product development and clinical trials. Image via Getty Images

Houston medical device startup closes $6M series A

money moves

A Houston-based medical device company born out of the Texas Medical Center has closed its series A round of funding.

Ictero Medical's oversubscribed $6 million round was led by MedTex Ventures, S3 Ventures, and an undisclosed strategic investor, according to a news release. The company's novel cryoablation system was designed to treat high-risk gallstone disease patients and provide a less invasive and lower risk alternative to gallbladder removal surgery — something over 1 million Americans undergo annually.

“Our technology provides an immediate solution for critically ill patients who currently have no good treatment options, and also has the potential to benefit healthier patients who want to avoid surgery,” says Ictero Co-Founder and CEO Matthew Nojoomi in the release.

Recently, Ictero Medical entered into a partnership with Houston medical device development firm Biotex. The collaboration provides the company with engineering resources and in-house manufacturing tools. Ictero also received capital support from MedTex Ventures through its Biotex Medical Device Fund.

“We are excited about working with the Ictero team to advance its technology, which we believe can significantly improve patient experiences and outcomes by providing a non-surgical alternative to treating gallbladder disease,” says Biotex CEO Ashok Gowda in the release.

The fresh funds will be put toward further product development and initial clinical testing.

“MedTex Ventures is enthusiastic about Ictero’s novel cryoablation technology and its potential to solve the unmet need of inoperable patients with gallbladder disease,” says John Fichthorn, CIO of MedTex Ventures, in the news release. “Equally important is the team. We believe the combination of Ictero and Biotex’s technical capabilities, alongside the support from key investors with commercial experience, such as S3 Ventures, position the company for long term success.”

Ictero was founded as a part of the Texas Medical Center’s Biodesign Fellowship program in 2018. Since launch, the company has received a Phase I NSF grant and closed a $1 million seed round co-led by the Texas Medical Center Venture Fund and Texas HALO Fund.

“Ictero is at the forefront of pioneering cryotherapy for gallstone disease, and S3 Ventures is excited about the potential for Ictero’s novel solution to rapidly bring an impactful outcome to patients,” says Kim Rodriguez, venture partner at S3, in the release. “Our research suggests a substantial opportunity to help patients suffering from gallstone disease who are dependent on drainage catheters or too sick for surgery. We are joining a solid investment syndicate in supporting a very capable team.”

Four Houston companies showed the city what they're made of at TMCx's recent Demo Day. Courtesy of TMCx

Houston-based medical device companies pitch at TMCx Demo Day

Local legends

Earlier this month, 16 medical device companies wrapped up their time at the Texas Medical Center's accelerator program and pitched their companies to fellow health professionals, guests, and more. While each made important connections in the local ecosystem during the program, a quarter of the entrepreneurs had roots in Houston already.

Four of the 16 TMCx09 companies that are headquartered in Houston. They have built solutions within sepsis, surgery, and transplant spaces in health care. Here's a little more about the homegrown companies that pitched at the event.

CorInnova

Photo via corinnova.com

The standard practice for acute heart failure patients is very invasive, says William Altman, CEO of CorInnova.

"The problem with existing devices is that they have invasive blood contact," Altman says. "Problem with that is blood contact is bad. It can cause up to 15 percent rate of stroke, which could kill you, and after five to seven days it provides 10 percent rate of blood destruction and has a 47 percent rate of kidney disfunction."

CorInnova's technology features a device that can be easily inserted through a 1-inch incision, and then be used for increase blood pumping by 50 percent.

"Surgeons tell us this is less invasive than minimally invasive aortic valve replacement, which is a widely done surgery, so this promises widespread adoption for our technology as we get it approved," Altman says.

The human prototype is expected to be ready in two years, with the next year being focused on animal studies. CorInnova is raising $12 million to accomplish its goals.

Ictero Medical

Getty Images

An estimated 10 to 15 percent of the United States population will get a gallstone in their lifetime. Should one of those stones cause trouble or blockages, the only solution is to remove the gallbladder completely through surgery. However, Matthew Nojoomi, CEO and co-founder of Ictero Medical, has another idea.

Ictero Medical has created a minimally invasive treatment that uses cryoablation to defunctionize the gallbladder without having to remove it.

"The CholeSafe System not only treats the source of the disease, but it leverages existing clinical workflows that doctors use to access the gallbladder," says Nojoomi, adding that the process only uses mild station and pain control.

The company expects to get to humans in the next two years, and has launched a financing round.

PATH EX

path ex

Photo via tmc.com

Currently, sepsis is hard to identify in patience. Even if a patient is in a hospital, and that hospital knows the patient has sepsis, the individual still has a 38 percent chance of dying, says Sinead Miller, CEO of PATH EX.

"Right now the problems associated with sepsis are very clear," she says. "It's the leading cause of death in our ICUs, and it's also associated with the highest hospital cost and readmission rates."

PATH EX's technology allows medical professionals to better diagnose and treat sepsis. The PATH EX therapeutic device can be hooked up to a patient and flow his or her blood through the machine to capture bacteria, clean and recirculate the blood, and faster diagnose what sort of bacteria the patient has attracted. The device technology is similar to hemo hemodialysis, Miller explains.

The Houston company, which recently won big at the Ignite Healthcare Network's Fire Pitch Competition, was named an honoree within the Johnson and Johnson Breakthrough Medical Technologies Quickfire Challenge.

The company was recently received clearance from the Food and Drug Administration as a breakthrough device technology. PATH EX closed its $615,000 seed round — with plans for a series A next year — and has received $1 million in SBIR grant funding. The company was founded two years ago, and relocated to call Houston HQ this year.

Volumetric

Jordan Miller/Rice University

Volumetric is banking on their technology being among the inventions that will lead the medical industry into the future. The human tissue-printing technology company has created the 3D printer and the "ink" that can create whole organs for transplant.

"We can create complicated vascular architectures inside of soft water-based gels, in this case, mimicking the structure and function of human lung tissue," says Jordan Miller, CEO. "We can oxygenate red blood cells."

The company is commercializing its technology and has three streams of revenue, which as generated almost $1 million in revenue in Volumetric's second year. The company is also in the process of closing its seed round of fundraising.

Earlier this year, the startup, which works out of Rice University, was featured on the cover of Science magazine.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston tech companies recognized for creating top inventions of the year

best of the rest

Innovations from three Houston companies have been crowned among the top inventions of the year.

Time magazine’s "200 Best Inventions of 2024" identified top innovations across consumer goods, home health, robotics, sustainability, and two dozen other categories.

Fervo Energy, a provider of geothermal power, was recognized the Green Energy category for its FervoFlex system. As Time explains, the system enables horizontal drilling into hot rock under the earth’s surface and pumping in water to generate hot water and steam. The geothermal energy that’s produced can be stored and released for future use by Fervo customers.

Jack Norbeck, Fervo’s co-founder and chief technology officer, predicts that by 2050, geothermal energy will become “the backbone of the decarbonized energy system.”

In September, Fervo secured a $100 million bridge loan for the first phase of its ongoing Cape Station project in Utah, which is being touted as the world’s largest geothermal energy plant. Slated for completion in June 2026, this initial phase is expected to generate 90 megawatts of renewable energy. Ultimately, the plant is supposed to supply 400 megawatts of clean energy by 2028 for customers in California.

Time also lauded NanoTech Materials among its Manufacturing and Materials honorees for its Insulative Ceramic Particle. This powder can be added to materials like drywall or shingles to improve fire resistance and decrease heat penetration, according to Time. NanoTech’s Wildfire Shield coating for buildings contains the powder. Wildfire Shield prevents damage to materials and harm from noxious smoke.

NanoTech’s other product, Cool Roof Coat, is painted on a building to decrease HVAC use. This year, NanoTech moved into a 43,000-square-foot space in Katy, Texas, and brought on new partners that expanded the company's reach in the Middle East and Singapore.

The third Houston company to be praised by Time is BiVACOR — named to its Experimental category of the list. This year, the company’s artificial heart has kept three U.S. patients alive long enough to wait for donor organs, according to Time, the first of these operations took place this summer in Houston.

Dr. William Cohn, chief medical officer of BiVACOR, previously told InnovationMap that while the Total Artificial Heart is being used currently as a "bridge-to-transplant" device, he believes it has the potential to be a permanent solution for the 200,000 patients who die of heart failure annually. Last year, only around 4,000 patients were able to receive heart transplants.

The full list of this year's top inventions is available online.

Houston researchers secure funding for superconductivity project

fresh funding

Researchers at the Department of Physics at the University of Houston and Texas Center for Superconductivity have received a second-year funding from global leader in business of invention Intellectual Ventures to continue their work on exploring superconductivity,

The project, which is led by Paul C. W. Chu, T.L.L. Temple Chair of Science, professor of physics and founding director of the TcSUH and assistant professor of physics and a new TcSUH principal investigator Liangzi Deng, has been awarded $767,000 to date.

“Working with IV gives us the freedom known for scientific pursuit and at the same time provides intellectual guidance and assistance in accord with the mission goal,” Chu says in a news release.

The researchers are working on making superconductivity easier to achieve. At room temperature and normal atmospheric pressure is where the researchers are looking to simplify superconductivity. One finding from Chu and Deng’s team is called pressure-quench protocol, or PQP.The PQP will help maintain key properties (like superconductivity) in certain materials after the high pressure needed to create them is removed.

“Intellectual Ventures funded this research because Paul Chu is one of the acknowledged thought leaders in the area of superconductivity with a multi-decade track record of scientific innovation and creativity,” Brian Holloway, vice president of IV’s Deep Science Fund and Enterprise Science Fund, adds. “The work led by Chu and Deng on pressure quenching could result in game-changing progress in the field. We are very excited about the preliminary results from the first year and we look forward to continuing this collaboration.”

The project showed early success the first year, as the research used a special system to synthesize materials under high temperatures and pressure. The second-year projects will include the investigation of pressure-induced/enhanced superconductivity in cuprates and hydrides.

“If successful, UH will once again break the record for the highest superconducting Tc at atmospheric pressure,” Deng says in the release. “Additionally, we will collaborate closely with theorists to uncover the mechanism of PQP. Our research has far-reaching implications, with the potential to extend beyond superconductors to other material systems.”

------

This article originally ran on EnergyCapital.